The U.S. Food and Drug Administration has lifted the clinical hold on GH Research’s Investigational New Drug Application for GH001, clearing the way for the company to initiate its global pivotal Phase 3 program in 2026. Dr. Velichka Valcheva, CEO of GH Research, described the decision as a major milestone that positions GH001 as a potential ultra-rapid and durable treatment option for patients with treatment-resistant depression. Management expects to meet with FDA officials in the coming months to finalize the trial design and dosing regimen for the pivotal study.

In February 2025, GH Research reported top-line results from its Phase 2b trial of GH001, an inhalable bufotenin candidate. The trial met its primary endpoint, with participants experiencing an average reduction of 15.2 points on the Montgomery-Åsberg Depression Rating Scale by Day 8, compared with a 0.3-point increase in the placebo group (difference of 15.5 points; p<0.0001). These data underscore the rapid onset and sustained remission observed with GH001 following infrequent, short clinic visits.

Following a recent management call, Guggenheim analyst Eddie Hickman reiterated a Buy rating on GH Research and set a price target that implies an approximate 83.5% upside from current levels. The firm cited the FDA’s clearance, strong Phase 2b data and a favorable competitive landscape as key drivers. Trading volumes have surged as investors position for upcoming Phase 3 catalysts, and market capitalization now approaches the high-nine-figure range.